Literature DB >> 12551861

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women.

Paul M Ridker1, Julie E Buring, Nancy R Cook, Nader Rifai.   

Abstract

BACKGROUND: The metabolic syndrome describes a high-risk population having 3 or more of the following clinical characteristics: upper-body obesity, hypertriglyceridemia, low HDL, hypertension, and abnormal glucose. All of these attributes, however, are associated with increased levels of C-reactive protein (CRP). METHODS AND
RESULTS: We evaluated interrelationships between CRP, the metabolic syndrome, and incident cardiovascular events among 14 719 apparently healthy women who were followed up for an 8-year period for myocardial infarction, stroke, coronary revascularization, or cardiovascular death; 24% of the cohort had the metabolic syndrome at study entry. At baseline, median CRP levels for those with 0, 1, 2, 3, 4, or 5 characteristics of the metabolic syndrome were 0.68, 1.09, 1.93, 3.01, 3.88, and 5.75 mg/L, respectively (P(trend) <0.0001). Over the 8-year follow-up, cardiovascular event-free survival rates based on CRP levels above or below 3.0 mg/L were similar to survival rates based on having 3 or more characteristics of the metabolic syndrome. At all levels of severity of the metabolic syndrome, however, CRP added prognostic information on subsequent risk. For example, among those with the metabolic syndrome at study entry, age-adjusted incidence rates of future cardiovascular events were 3.4 and 5.9 per 1000 person-years of exposure for those with baseline CRP levels less than or greater than 3.0 mg/L, respectively. Additive effects for CRP were also observed for those with 4 or 5 characteristics of the metabolic syndrome. The use of different definitions of the metabolic syndrome had minimal impact on these findings.
CONCLUSIONS: These prospective data suggest that measurement of CRP adds clinically important prognostic information to the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12551861     DOI: 10.1161/01.cir.0000055014.62083.05

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  472 in total

1.  Effects of etanercept in patients with the metabolic syndrome.

Authors:  L Elizabeth Bernstein; Jacqueline Berry; Sunnie Kim; Bridget Canavan; Steven K Grinspoon
Journal:  Arch Intern Med       Date:  2006-04-24

2.  Evidence for an association between type 1 diabetes and premature carotid atherosclerosis in childhood.

Authors:  M E Atabek; O Pirgon; S Kurtoglu; H Imamoglu
Journal:  Pediatr Cardiol       Date:  2006 Jul-Aug       Impact factor: 1.655

Review 3.  Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.

Authors:  Deborah J Wake; Brian R Walker
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 4.  C-reactive protein and risk of cardiovascular disease: evidence and clinical application.

Authors:  Paul M Ridker; Shari S Bassuk; Peter P Toth
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

5.  Associations of components of adult height with coronary heart disease in postmenopausal women: the British women's heart and health study.

Authors:  D A Lawlor; M Taylor; G Davey Smith; D Gunnell; S Ebrahim
Journal:  Heart       Date:  2004-07       Impact factor: 5.994

6.  Osteoarthritis of knee joint in metabolic syndrome.

Authors:  Abd El-Moaty Ali Afifi; Reham Magdy Shaat; OLa M Gharbia; Yosra El Boghdadi; Mervat Mohammad El Eshmawy; Ola Ali El-Emam
Journal:  Clin Rheumatol       Date:  2018-07-23       Impact factor: 2.980

7.  Distribution and correlates of the metabolic syndrome in adults living in the San Juan Metropolitan Area of Puerto Rico.

Authors:  Cynthia M Pérez; Ana P Ortiz; Manuel Guzmán; Erick Suárez
Journal:  P R Health Sci J       Date:  2012-09       Impact factor: 0.705

Review 8.  Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism.

Authors:  Eliza B Geer; Julie Islam; Christoph Buettner
Journal:  Endocrinol Metab Clin North Am       Date:  2014-03       Impact factor: 4.741

Review 9.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

10.  Acute cardiovascular effects of firefighting and active cooling during rehabilitation.

Authors:  Jefferey L Burgess; Michael D Duncan; Chengcheng Hu; Sally R Littau; Delayne Caseman; Margaret Kurzius-Spencer; Grace Davis-Gorman; Paul F McDonagh
Journal:  J Occup Environ Med       Date:  2012-11       Impact factor: 2.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.